Sanara MedTech Inc.
SMTIHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 9, 2026
Scan Results
Daily timeframeSanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. With a market capitalization of $322.0M, it sits in small-cap territory. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Market Cap
$322.0M
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
64.91
EPS (TTM)
$-0.04
EPS (Fwd)
$0.54
ROE
-1.3%
ROA
7.6%
Cash
$15.4M
Total Debt
$48.5M
Free CF
$5.7M
52W Change
2.9%
Annual Financials
Cash vs Debt
Where SMTI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SMTI finished 49.81% above its 150-day moving average ($23.23) and 50.65% above its 200-day moving average ($23.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SMTI overbought or oversold?
At the September 3, 2026 close, SMTI's RSI(14) was 70.5, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $15.4M in cash, though total debt stands at $48.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $5.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -1.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $45.8M (2022) to $103.1M (2025), reflecting a 125% increase over the period.
As with any equity investment, SMTI carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sanara MedTech Inc. and its sector.